Takeda and the Government of Indonesia Announce Strategic Partnership

JAKARTA - Takeda (TSE: 4502/NYSE: TAK) together with the Government of Indonesia, consisting of the Ministry of Health, the Ministry of Investment and Industrial Industrialization/BKPM and the Coordinating Ministry for Economic Affairs, today announced a strategic partnership to strengthen the Indonesian plasma industry ecosystem and expand access to life-saving PODP.

As part of this partnership, the Ministry of Health has designated Takeda as the pharmaceutical industry that can organize plasma fractionation to produce PODP. This designation allows Takeda to carry out plasma collection activities and fractionation processes gradually as part of the development of a national plasma industry ecosystem.

This step is an important milestone in strengthening Indonesia's health resilience while supporting the development of the national biopharmaceutical industry.

"This initiative reflects the commitment of the Government of Indonesia to build strategic industries in the health sector and ensure that the public has better access to important and innovative treatments," said the Minister of Health of the Republic of Indonesia, Budi Gunadi Sadikin.

"Through a partnership with Takeda, we hope to strengthen the national health system while preparing Indonesia to face future health challenges," he added.

This long-term initiative is the first in Southeast Asia. The focus is on building a sustainable high-quality plasma collection system and supporting large-scale PODP manufacturing. By utilizing Takeda's long experience in Indonesia, this partnership is expected to make Indonesia a center for plasma-related science development, plasma collection technology, and biopharmaceutical manufacturing and innovation.

"This partnership demonstrates Takeda's commitment to expanding access to PODP while supporting the development of a sustainable plasma ecosystem in Indonesia," said Ramy Riad, President, Plasma-Derived Therapies Takeda.

"Since introducing our first PODP in Indonesia earlier this year to investments in plasma industry infrastructure from upstream to downstream, we are proud to be able to expand our cooperation with the Indonesian Government. We hope that Takeda's global experience can support Indonesia's long-term goals in improving health services, creating high-skilled jobs, and strengthening the availability of life-saving and life-sustaining services and treatments. "explained Ramy.

As an initial development phase, Takeda will invest up to USD30 million (approximately Rp539 billion) over a two-year period to build several plasma banks in Indonesia. The results of this initial development phase will be the basis for Takeda and the Ministry of Health to evaluate the feasibility of the operational model before being developed into a national plasma bank network.

All plasma banks will utilize Takeda's global experience in plasma donor management and implement international quality and regulatory standards. This initiative is also expected to open up new job opportunities, including for health workers and laboratory technicians, as well as supporting human resource capacity building through training and knowledge transfer.

In parallel, Takeda will also study the potential and regulatory requirements for building a high-tech PODP manufacturing facility in Indonesia that can support domestic and global market needs. The development of this facility has the potential to strengthen Indonesia's position in the global supply chain of the health industry and drug manufacturing.

"This investment is a strategic investment. In addition to bringing new investments, this partnership also opens up opportunities for technology transfer, national human resource development, and job creation. This partnership not only strengthens Indonesia's health ecosystem, but also supports our vision to make Indonesia a regional center for health innovation and advanced pharmaceutical manufacturing," said Minister of Investment and Industrialization/Head of BKPM, Rosan P. Roeslani.

Global demand for PODP continues to increase. However, many countries in Southeast Asia, including Indonesia, still face challenges in ensuring the availability of this drug. Low levels of diagnosis and limited understanding of conditions that can be treated with PODP are still a major obstacle.

Through this partnership, Takeda and the Indonesian Government want to build a more reliable supply of plasma and PODP for patients in Indonesia while strengthening the global plasma industry ecosystem. By sharing best practices in plasma collection and processing, building local capabilities, increasing public awareness, and investing in the development of health workers, this initiative is expected to further improve the quality of patient services in Indonesia and in the Southeast Asian region.

The first plasma bank is targeted to start operating in 2027 and will be part of Takeda's BioLife plasma bank network. As long as the plasma fractionation facility in Indonesia is still in the review stage, the collected plasma will be processed through Takeda's global manufacturing network, while prioritizing the fulfillment of Indonesia's needs for PODP in accordance with applicable laws and regulations.